TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19696440

Group type: EXPERIMENTAL
Intervention: Sublingual house dust mite (HDM) immunotherapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 17355733

Group type: EXPERIMENTAL
Intervention: Clarithromycin (500 mg once daily for 6 months)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo (daily oral for 6 months)
Number of subjects: 81
Study: 15083446

Group type: EXPERIMENTAL
Intervention: Laterally wedged insoles with subtalar strapping (16 mm elevation)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Laterally wedged insoles with subtalar strapping (12 mm elevation)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Laterally wedged insoles with subtalar strapping (8 mm elevation)
Number of subjects: 62
Study: 12384899

Group type: EXPERIMENTAL
Intervention: Recliner-chair
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional hospital bed
Number of subjects: 0
Study: 9876598

Group type: EXPERIMENTAL
Intervention: Agitation and viscosity (in vitro variables)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Model I (cumulative percentage of paracetamol dissolved)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Model II (Weibull function parameters)
Number of subjects: 10
Study: 7925528

Group type: EXPERIMENTAL
Intervention: CGRP/PGE1 (5 micrograms CGRP plus 10 micrograms PGE1)
Number of subjects: 68
Study: 3072180

Group type: EXPERIMENTAL
Intervention: Behavioral interventions (relaxation and biofeedback therapies)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Medicated patients
Number of subjects: 0
Study: 30803434

Group type: EXPERIMENTAL
Intervention: Plasma metabolites
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Specific significant metabolites (pseudo‐uridine, indole‐3‐lactate, uric acid, isothreonic acid, and creatinine)
Number of subjects: 0
Study: 28872272

Group type: EXPERIMENTAL
Intervention: HIV-POCT in South Africa
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HIV-POCT in Zambia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HIV-POCT with enhanced QA interventions in South Africa
Number of subjects: 0

Group type: COMPARATOR
Intervention: HIV-POCT
Number of subjects: 0
Study: 26571887

Group type: EXPERIMENTAL
Intervention: Low-frequency electric stimulation
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Medication (estazolam 1 mg orally)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo (starch capsules)
Number of subjects: 120
Study: 23383959

Group type: EXPERIMENTAL
Intervention: Caffeine (3 mg kg(‐1))
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo (500 ml)
Number of subjects: 11
Study: 20189611

Group type: EXPERIMENTAL
Intervention: AST-120 treatment (6 g/d)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 50
Study: 19320241

Group type: EXPERIMENTAL
Intervention: LPV/r monotherapy
Number of subjects: 83

Group type: COMPARATOR
Intervention: Standard triple-drug regimen
Number of subjects: 83
Study: 16501728

Group type: EXPERIMENTAL
Intervention: Community outreach case-finding intervention
Number of subjects: 380

Group type: COMPARATOR
Intervention: Passive case-finding in control communities
Number of subjects: 380
Study: 12818245

Group type: EXPERIMENTAL
Intervention: Oral anticoagulant therapy (warfarin 10, 7.5, and 5 mg for three consecutive days)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Low-molecular weight heparin (LMWH) administered in a fixed dose of 200 anti-Xa IU/kg body weight in one subcutaneous injection daily
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Both OAT and LMWH
Number of subjects: 33
Study: 10699698

Group type: EXPERIMENTAL
Intervention: Adult self-inflatable bag (maximum volume, 1500 ml)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Paediatric self-inflatable bag (maximum volume, 700 ml)
Number of subjects: 40
Study: 9330145

Group type: EXPERIMENTAL
Intervention: Ultrasonographic-release technique
Number of subjects: 103

Group type: COMPARATOR
Intervention: Conventional open release
Number of subjects: 103
Study: 8418695

Group type: EXPERIMENTAL
Intervention: Intraoperative radiotherapy (IORT) administered to the gastric bed (20 Gy using 11 to 15 MeV electrons)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Conventional therapy (gastrectomy alone or resection and postoperative external beam radiotherapy to the upper abdomen (50 Gy using 6 to 10 mV photons))
Number of subjects: 41
Study: 3674575

Group type: COMPARATOR
Intervention: 0.0 ppm SO2
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: 0.2 ppm SO2
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: 0.4 ppm SO2
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: 0.6 ppm SO2
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Exercise during exposure
Number of subjects: 85

Group type: COMPARATOR
Intervention: 1 day or 1 week after exposure
Number of subjects: 85
Study: 30404599

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided lumbar facet joint injections
Number of subjects: 50

Group type: COMPARATOR
Intervention: Low dose computed tomography (CT) guidance for lumbar facet joint injections
Number of subjects: 50
Study: 29046304

Group type: EXPERIMENTAL
Intervention: Look AHEAD
Number of subjects: 2404

Group type: EXPERIMENTAL
Intervention: DPP
Number of subjects: 2404
Study: 26293583

Group type: EXPERIMENTAL
Intervention: Silexan 80 mg once daily for 10 weeks
Number of subjects: 170

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 170
Study: 23375194

Group type: EXPERIMENTAL
Intervention: Interceptor(®) Flavor Tabs(®) at a minimum dose of 0.5 mg/kg (0.23 mg/lb)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Sentinel(®) Flavor Tabs(®) at a minimum dose of 0.5 mg/kg (0.23 mg/lb)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo control group
Number of subjects: 36
Study: 21968154

Group type: EXPERIMENTAL
Intervention: Single-incision laparoscopic appendectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional laparoscopic appendectomy
Number of subjects: 0
Study: 18001269

Group type: EXPERIMENTAL
Intervention: Standard overnight TPN (0.16 gN.kg(‐1) of body weight.day(‐1) and 30 kcal.kg(‐1) of body weight.day(‐1))
Number of subjects: 12

Group type: COMPARATOR
Intervention: Saline infusion (Control)
Number of subjects: 12
Study: 20535793

Group type: EXPERIMENTAL
Intervention: Adalimumab treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0
Study: 15748874

Group type: EXPERIMENTAL
Intervention: Sweet taste
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Sour taste
Number of subjects: 32
Study: 12013374

Group type: EXPERIMENTAL
Intervention: Specific training in one of the conditions (resolved or unresolved harmonics)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 9917588

Group type: EXPERIMENTAL
Intervention: Vacuum cementing technique (proximal and distal drainage)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Conventional cementing technique (control group)
Number of subjects: 70
Study: 8048859

Group type: EXPERIMENTAL
Intervention: Continuous infusion of 1.0 mg/h of tissue plasminogen activator (group A)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 20 mg bolus followed by an infusion of 1.0 mg/h of tissue plasminogen activator (group B)
Number of subjects: 45
Study: 2972631

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS) and etofenamate 10% gel, 3‐5 cm daily on the day of TENS therapy, and the same dose twice daily on the other days
Number of subjects: 30

Group type: COMPARATOR
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 30
Study: 31216821

Group type: COMPARATOR
Intervention: Quadruple therapy group
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Simultaneous probiotic group
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: There after probiotic group
Number of subjects: 300
Study: 27575011

Group type: EXPERIMENTAL
Intervention: Vildagliptin
Number of subjects: 16

Group type: COMPARATOR
Intervention: Glimepiride
Number of subjects: 16
Study: 27486173

Group type: EXPERIMENTAL
Intervention: Aspiration thrombectomy after intravenous alteplase (IAT)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Intravenous alteplase alone
Number of subjects: 108
Study: 25186158

Group type: EXPERIMENTAL
Intervention: Automated closed-loop insulin delivery
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sensor-augmented pump therapy
Number of subjects: 30
Study: 21737235

Group type: EXPERIMENTAL
Intervention: Continuous veno-venous hemodiafiltration (CVVHDF)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intravenous furosemide
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Continuous veno-venous hemodiafiltration (CVVHDF) and Intravenous furosemide
Number of subjects: 40
Study: 20009055

Group type: EXPERIMENTAL
Intervention: Tarenflurbil, 800 mg, administered twice a day
Number of subjects: 1684

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1684
Study: 17335419

Group type: EXPERIMENTAL
Intervention: 0.2 mg/mL rhBMP‐2
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 0.05 mg/mL rhBMP‐2
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 21
Study: 15128630

Group type: EXPERIMENTAL
Intervention: Electronic questionnaires
Number of subjects: 1333

Group type: COMPARATOR
Intervention: Postal questionnaires
Number of subjects: 1333

Group type: EXPERIMENTAL
Intervention: Knowledge and practice questions
Number of subjects: 1333
Study: 11511121

Group type: EXPERIMENTAL
Intervention: Pentasaccharide (low, medium, or high dose) administered daily for 5 to 7 days, intravenously on the first day, then subcutaneously
Number of subjects: 333

Group type: COMPARATOR
Intervention: Pentasaccharide
Number of subjects: 333
Study: 9683397

Group type: EXPERIMENTAL
Intervention: Test product (milk fermented by Lactobacillus acidophilus with 2.5% fructo-oligosaccharides, 0.5% vegetable oil, and 0.5% milk fat)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Reference product (traditional yogurt with 1% milk fat)
Number of subjects: 30
Study: 7810083

Group type: EXPERIMENTAL
Intervention: Magnesium (Mg) treatment with 50 mmol Mg for the first 24 hours and 12 mmol Mg for the subsequent 24 hours
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study: 2898503

Group type: EXPERIMENTAL
Intervention: 4% chlorhexidine gluconate
Number of subjects: 0

Group type: COMPARATOR
Intervention: povidone‐iodine
Number of subjects: 0

Group type: COMPARATOR
Intervention: triclocarban medicated soap and water
Number of subjects: 0
Study: 29128507

Group type: EXPERIMENTAL
Intervention: Unloading shoes (ASICS GEL‐Melbourne OA)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Conventional shoes
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Unloading shoes
Number of subjects: 164
Study: 26878748

Group type: EXPERIMENTAL
Intervention: 1.2% Rosuvastatin Gel
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 1.2% Atorvastatin Gel
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo Gel
Number of subjects: 90
Study: 24560157

Group type: EXPERIMENTAL
Intervention: DASH-style diet
Number of subjects: 57

Group type: COMPARATOR
Intervention: Low-oxalate diet
Number of subjects: 57
Study: 23883311

Group type: EXPERIMENTAL
Intervention: Terbutaline sulfate fast dissolving sublingual films
Number of subjects: 4

Group type: COMPARATOR
Intervention: Conventional oral tablets
Number of subjects: 4
Study: 20664891

Group type: EXPERIMENTAL
Intervention: Moderate dose of ethanol (35 g)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 17716753

Group type: EXPERIMENTAL
Intervention: Right ventricular dysfunction (RVD)
Number of subjects: 520

Group type: EXPERIMENTAL
Intervention: Combination of RV dilation and IVC broadening
Number of subjects: 520

Group type: EXPERIMENTAL
Intervention: RVD, RVED/LVED ratio, SPAP
Number of subjects: 520

Group type: EXPERIMENTAL
Intervention: RVED/LVED >0.67 and/or SPAP >60 mm Hg
Number of subjects: 520

Group type: EXPERIMENTAL
Intervention: Hemodynamic instability, 14-day clinical outcomes, SPAP
Number of subjects: 520
Study: 17083839

Group type: EXPERIMENTAL
Intervention: Alpha-adrenoceptor agonists
Number of subjects: 46

Group type: COMPARATOR
Intervention: PFME
Number of subjects: 46
Study: 11869839

Group type: EXPERIMENTAL
Intervention: Chronic lisinopril therapy
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Increased dose of lisinopril
Number of subjects: 28
Study: 10022449

Group type: EXPERIMENTAL
Intervention: L‐T4 treatment (group A, n = 100) with an initial dose of 150 microg daily
Number of subjects: 202

Group type: COMPARATOR
Intervention: No treatment (group B, n = 102)
Number of subjects: 202
Study: 7784246

Group type: EXPERIMENTAL
Intervention: DGAVP (2 mg single dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chronic treatment with DGAVP (1 mg/day for 2 weeks)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chronic treatment with DGAVP
Number of subjects: 0

Group type: COMPARATOR
Intervention: Acute treatment with DGAVP
Number of subjects: 0
Study: 2207869

Group type: EXPERIMENTAL
Intervention: Flurbiprofen sodium (0.03%)
Number of subjects: 0
Study: 359246

Group type: EXPERIMENTAL
Intervention: Diflunisal 500 mg
Number of subjects: 270

Group type: COMPARATOR
Intervention: Diflunisal 375 mg or 500 mg
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Diflunisal (multiple doses)
Number of subjects: 270

Group type: COMPARATOR
Intervention: Aspirin 600 mg
Number of subjects: 270

Group type: COMPARATOR
Intervention: Oxyphenbutazone 200 mg t.i.d.
Number of subjects: 270

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 270
Study: 29603100

Group type: EXPERIMENTAL
Intervention: Dietary zinc intake (7.04 ± 4.28 mg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dietary zinc intake
Number of subjects: 0

Group type: COMPARATOR
Intervention: Serum zinc concentration
Number of subjects: 0
Study: 27311073

Group type: EXPERIMENTAL
Intervention: Nerve tubes used for repair of 15 digital nerves and 13 median and ulnar nerves.
Number of subjects: 41

Group type: COMPARATOR
Intervention: Primary end-to-end sutures without nerve tubes.
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Nerve tubes used for repair of median and ulnar nerves.
Number of subjects: 41

Group type: COMPARATOR
Intervention: Primary end-to-end sutures without nerve tubes for median and ulnar nerves.
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Nerve tubes used for repair of finger injuries.
Number of subjects: 41

Group type: COMPARATOR
Intervention: Primary end-to-end sutures without nerve tubes for finger injuries.
Number of subjects: 41
Study: 25345953

Group type: EXPERIMENTAL
Intervention: Vildagliptin (50 mg, twice daily, n=36)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Acarbose (50 mg, three times a day, n=30)
Number of subjects: 66
Study: 22707271

Group type: EXPERIMENTAL
Intervention: Green tea extract (1.06 g)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Green tea extract
Number of subjects: 50
Study: 20841390

Group type: EXPERIMENTAL
Intervention: Folic acid supplement (1 mg/day)
Number of subjects: 871

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 871
Study: 18947094

Group type: EXPERIMENTAL
Intervention: Nurse-run, physician-monitored clinics
Number of subjects: 23
Study: 16822132

Group type: EXPERIMENTAL
Intervention: Ideal-navigator model for indoor navigation using a partially observable Markov decision process
Number of subjects: 0

Group type: COMPARATOR
Intervention: Human navigation performance
Number of subjects: 0

Group type: COMPARATOR
Intervention: Visual perception
Number of subjects: 0

Group type: COMPARATOR
Intervention: Memory, spatial updating strategy, decision strategy
Number of subjects: 0
Study: 12783370

Group type: EXPERIMENTAL
Intervention: Imatinib (Gleevec)
Number of subjects: 12000
Study: 10893682

Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 9294801

Group type: EXPERIMENTAL
Intervention: Intramedullary nailing (IM)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Percutaneous pinning (PP)
Number of subjects: 2
Study: 8421719

Group type: EXPERIMENTAL
Intervention: Soft foot orthotics in addition to an exercise program
Number of subjects: 20

Group type: COMPARATOR
Intervention: Exercise program (control group)
Number of subjects: 20
Study: 3534570

Group type: EXPERIMENTAL
Intervention: Allopurinol (100 mg three times daily)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 60
Study: 29193558

Group type: EXPERIMENTAL
Intervention: Short implants (SIs), 6.5 to 8.5mm long
Number of subjects: 52

Group type: COMPARATOR
Intervention: Sinus augmentation (SA) and implants ≥10mm long
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Short implants (SIs)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Sinus augmentation (SA)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Short implants (SIs) and Sinus augmentation (SA)
Number of subjects: 52
Study: 27362788

Group type: EXPERIMENTAL
Intervention: Tenofovir (TFV) 1% gel
Number of subjects: 248

Group type: COMPARATOR
Intervention: Placebo rectal gel
Number of subjects: 248
Study: 24377326

Group type: EXPERIMENTAL
Intervention: Methylphenidate (low dose: 5 mg × 3)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Methylphenidate (normal dose: 20 mg × 3)
Number of subjects: 29

Group type: COMPARATOR
Intervention: No medication
Number of subjects: 29
Study: 22430907

Group type: EXPERIMENTAL
Intervention: Total Extraperitoneal Inguinal Hernioplasty (TEP)
Number of subjects: 660

Group type: COMPARATOR
Intervention: Lichtenstein repair
Number of subjects: 660
Study: 19765066

Group type: EXPERIMENTAL
Intervention: Competitive distance running (ER)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sedentary controls (SC)
Number of subjects: 24
Study: 18370580

Group type: EXPERIMENTAL
Intervention: Weekly reflexology treatments for 4 weeks
Number of subjects: 21

Group type: COMPARATOR
Intervention: Friendly visits for 4 weeks (Control)
Number of subjects: 21
Study: 16201210

Group type: EXPERIMENTAL
Intervention: Low-frequency noise (LFN) at 50 dB(A)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Reference noise (broadband noise without dominant low frequency content) at 50 dB(A)
Number of subjects: 96
Study: 11684984

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 66
Study: 9727786

Group type: EXPERIMENTAL
Intervention: Exercise plus education (Exercise group)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Education (Control group)
Number of subjects: 126
Study: 7949827

Group type: EXPERIMENTAL
Intervention: Proper diagnosis and treatment of hypertensive disorders in pregnancy
Number of subjects: 0
Study: 3056431

Group type: EXPERIMENTAL
Intervention: Gemfibrozil 600 mg bid
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Clofibrate 1000 mg bid
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 19333169

Group type: EXPERIMENTAL
Intervention: Clonidine-bupivacaine nerve-stimulator guided injection (9 mL bupivacaine 0.5% and 1 mL clonidine 150 mcg/mL)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Bupivacaine guided injection (9 mL bupivacaine 0.5% and 1 mL saline)
Number of subjects: 80
Study: 290650

Group type: EXPERIMENTAL
Intervention: Phosphates added to pre-sweetened and non-presweetened ready-to-eat cereals
Number of subjects: 145

Group type: COMPARATOR
Intervention: Non-cereal eaters
Number of subjects: 145
Study: 31937730

Group type: EXPERIMENTAL
Intervention: ASHAs with monetary incentive
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Health education (HE)
Number of subjects: 162
Study: 31780418

Group type: EXPERIMENTAL
Intervention: Clopidogrel as mono antiplatelet therapy (MAPT) after COBRA PzF NCS implantation
Number of subjects: 77
Study: 28494920

Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept (2 mg/0.05 mL at baseline, 4 weeks, and 8 weeks; reviewed every 4 weeks thereafter with injections as needed)
Number of subjects: 232

Group type: COMPARATOR
Intervention: PRP standard care (single spot or multispot laser at baseline, fractionated fortnightly thereafter, assessed every 8 weeks and treated as needed)
Number of subjects: 232
Study: 25986590

Group type: EXPERIMENTAL
Intervention: Lithium plus Treatment As Usual (TAU)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo plus Treatment As Usual (TAU)
Number of subjects: 0
Study: 23870047

Group type: EXPERIMENTAL
Intervention: Internet administration of the Edinburgh Depression Scale
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Telephone administration of the Edinburgh Depression Scale
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Pen-and-paper administration of the Edinburgh Depression Scale
Number of subjects: 91

Group type: COMPARATOR
Intervention: Overall comparison across all groups
Number of subjects: 91
Study: 21341893

Group type: EXPERIMENTAL
Intervention: Culturally adapted one-session treatment (OST-CA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standard one-session treatment (OST-S)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Self-help control
Number of subjects: 0
Study: 19489187

Group type: EXPERIMENTAL
Intervention: New toothpaste containing 8.0% arginine, calcium carbonate, and 1450 ppm fluoride (MFP)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Commercial sensitive toothpaste containing 2% potassium ion and 1450 ppm fluoride (NaF)
Number of subjects: 77
Study: 17823446

Group type: EXPERIMENTAL
Intervention: Dairy intervention group (n = 39) receiving daily approximately 1200 mg Ca and 7.5 microg vitamin D3 via fortified dairy products and biweekly nutrition education sessions
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Calcium‐supplemented group (n = 26) receiving a total of 1200 mg Ca/d
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control group (n = 36)
Number of subjects: 101
Study: 15114779

Group type: EXPERIMENTAL
Intervention: Low-molecular heparin dalteparin (n = 31)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Non-fractionated heparin (n = 17)
Number of subjects: 51
Study: 11711015

Group type: EXPERIMENTAL
Intervention: Participation of an academic research group in the study
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Research topic
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Financial incentive
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Professional obligation
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Overall recruitment
Number of subjects: 165